Reduction of cisplatin-induced emesis by a selective neurokinin-1- receptor antagonist.
New England Journal of Medicine.
Times cited: 307
Rationale for the use of a single fixed intravenous dolasetron dose for the prevention of cisplatin-induced nausea and vomiting: Pooled analysis of 14 clinical trials.
Supportive Care in Cancer.
Times cited: 4
Prevention of acute emesis in cancer patients following high-dose cisplatin with the combination of oral dolasetron and dexamethasone.
Journal of Clinical Oncology.
Times cited: 24